Furthermore, device use within the GLP-1 using population declined only slightly, so that the overall impact on device use was less than 1%: While GLP-1s have been available for over 20 years, what has captured analysts attention over the past quarter are the dramatic increases in the percentage of body weight lost
The names appear because they ride on recognition and trust, not because the sticker holds the molecule
Current evidence regarding the impact of GLP-1 receptor agonists on ophthalmic diseases remains inconsistent. Retinopathy remains the dominant concern Much of the ophthalmic attention surrounding GLP-1 therapies traces back to DR
Do higher semaglutide doses always produce better weight loss results
Medications that promote weight gain, such as certain antipsychotics, corticosteroids, or some antidepressants, can blunt weight loss effects
This pattern is similar to other GLP-1based medications, where increasing the dose can improve results but also raises the chance of side effects
